We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

MAIA Biotechnology Inc (MAIA) USD0.0001

Sell:$3.66 Buy:$3.73 Change: $0.20 (5.10%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
Sell:$3.66
Buy:$3.73
Change: $0.20 (5.10%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
Sell:$3.66
Buy:$3.73
Change: $0.20 (5.10%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Contact details

Address:
444 West Lake Street
Suite 1700, Suite 1700
CHICAGO
60606
United States
Telephone:
+1 (312) 4168592
Website:
https://maiabiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MAIA
ISIN:
US5526411021
Market cap:
$86.48 million
Shares in issue:
21.84 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Vlad Vitoc
    Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Jeffrey Himmelreich
    Principal Financial and Accounting Officer, Head of Finance
  • Sergei Gryaznov
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.